NCT00111787 - Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 11, 2005

Primary Completion Date

November 1, 2006

Study Completion Date

November 1, 2006

Conditions

Neoplasms, Breast

Interventions

DRUG

Lapatinib

Daily-monotherapy \[1500 milligrams (mg)\] for 14 days, then daily combination therapy (with weekly paclitaxel) for 12 weeks

DRUG

Paclitaxel

Weekly (80mg/m\^2) combination therapy (with daily Lapatinib) for 12 weeks

Trial Locations (25)

1004

GSK Investigational Site, Tunis

1007

GSK Investigational Site, Tunis

2031

GSK Investigational Site, Randwick

2170

GSK Investigational Site, Liverpool

2560

GSK Investigational Site, Campbelltown

3000

GSK Investigational Site, Sfax

3029

GSK Investigational Site, Sfax

3128

GSK Investigational Site, Box Hill

GSK Investigational Site, Ringwood East

4101

GSK Investigational Site, South Brisbane

5042

GSK Investigational Site, Bedford Park

17007

GSK Investigational Site, Girona

33136

GSK Investigational Site, Miami

46010

GSK Investigational Site, Valencia

52621

GSK Investigational Site, Ramat Gan

59020

GSK Investigational Site, Lille

60099

GSK Investigational Site, Zion

60637

GSK Investigational Site, Chicago

64100

GSK Investigational Site, Bayonne

75651

GSK Investigational Site, Paris

77030

GSK Investigational Site, Houston

M4N 3M5

GSK Investigational Site, Toronto

Unknown

GSK Investigational Site, Auckland

08035

GSK Investigational Site, Barcelona

SW3 6JJ

GSK Investigational Site, London